Bajaj Healthcare gets SEC-CDSCO nod to make and sell Cenobamate Tablets

Regulatory Product ApprovalBusiness Updates View source PDF

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+14.5%1-day move

₹305.80

prior close

₹313.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+6.5+8.8+9.2+9.6+14.5+12.8+12.8+12.8+10.4+10.2+27.9———

Up moveDown movePending

AI summary

Bajaj Healthcare has received a recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organisation to manufacture and market Cenobamate Tablets in India. Cenobamate is an anti-epileptic drug used to treat partial-onset seizures in adults. The SEC recommendation is a key step toward receiving final marketing approval from the Drug Controller General of India.

Likely market impact

Positive for the company as it adds a new neurology product to its portfolio, potentially boosting future revenue. Watch for final DCGI approval.